Skip to main content
Fig. 3 | BMC Cancer

Fig. 3

From: Randomized double-blind clinical trial comparing safety and efficacy of the biosimilar BCD-021 with reference bevacizumab

Fig. 3

Efficacy endpoint assessment results (pooled mITT population). Note: ORR — overall response rate; CR — complete response; CPR — confirmed complete response; UPR — unconfirmed partial response; SD — stable disease; PR — progressive disease. Note: 1 — Fisher’s exact test; 2 — Pearson chi-square test

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us